TREAT
2009
Trial to Reduce Cardiovascular Events with Aranesp Therapy
In 4,038 patients with type 2 diabetes, CKD and anaemia, darbepoetin alfa did not reduce death or cardiovascular events and doubled the risk of stroke compared with placebo.
Result
Efficacy: Composite of death or cardiovascular event; death or ESRDHR 1.05 · P = 0.41
Safety: Fatal or non-fatal strokeHR 1.92 (95% CI 1.38-2.68) · P < 0.001
Below 1 favours darbepoetin alfa, above 1 favours placebo.
- Subtopic
- Anaemia management
- Design
- Double-blind RCT
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- KDIGO 2026 Anaemia in CKD
- Source
- Pfeffer MA, et al. N Engl J Med. 2009;361(21):2019-2032.doi 10.1056/NEJMoa0907845
Discussion & critique
The stroke signal anchored conservative haemoglobin targets and an FDA black-box warning.